SCHEMBL6282260

SCHEMBL6282260

COC(=O)Cc1c(C)[nH]c2cc(C)ccc12

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.55
KDM4E B2RXH2 3/20 0.55
ALDH1A1 P00352 3/20 0.55
GAA P10253 2/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
MITF O75030 1/20 0.50
EGFR P00533 3/20 0.48
AKR1C2 P52895 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
KLK6 Q92876 1/20 0.45
NR4A2 P43354 1/20 0.44
ALOX15 P16050 1/20 0.44
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
HTT P42858 1/20 0.41
KIF11 P52732 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8292165 0.86 MCL1 (0.47) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL6288056 0.83 KDM4E (0.77) MAPTKDM4EALDH1A1GAAMEN1
SCHEMBL6287945 0.82 KIF11 (0.48) MAPTMEN1KMT2AEGFRAKR1C2
SCHEMBL1191332 0.82 KDM4E (0.69) MAPTKDM4EALDH1A1GAAEGFR
SCHEMBL6825323 0.78 SPR (0.60) MAPTKDM4EALDH1A1GAAMEN1
SCHEMBL8150389 0.78 PTGS2 (0.45) MAPT
SCHEMBL1757929 0.77 AKR1C2 (0.54) MAPTKDM4EALDH1A1GAAMEN1
SCHEMBL3005298 0.77 AKR1C2 (0.54) MAPTKDM4EALDH1A1GAAMEN1
SCHEMBL6825151 0.77 AKR1C2 (0.78) MAPTKDM4EALDH1A1GAAMEN1
SCHEMBL30604527 0.77 AKR1C2 (0.78) MAPTKDM4EALDH1A1GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887890-B2 Compounds exhibiting thrombopoietin-like activities CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-05-03 US disclosed
US-20030162724-A1 Compounds exhibiting thrombopoietin-like activities CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-08-28 US disclosed
EP-1291341-A1 COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-03-12 EP disclosed
CN-1068588-C 1H-indole-3-acetamide splA2 inhibitors LILLY CO ELI (US) 2001-07-18 CN disclosed
US-6252084-B1 THERAPY FOR SEPSIS SHOCK ELI LILLY AND COMPANY 2001-06-26 US disclosed
EP-0620215-B1 1H-indole-3-acetamide derivatives as sPLA2 inhibitors LILLY CO ELI (US) 1999-08-18 EP disclosed
US-5684034-A INHIBITORS OF HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2, TREATMENT OF SEPTIC SHOCK, TRAUMA, RESPIRATORY DISORDERS, RHEUMATIC ARTHRITIS, INHIBITORS OF ARACHIDONIC ACID RELEASE ELI LILLY AND COMPANY (US) 1997-11-04 US disclosed
CN-1098715-A PLA 2 inhibitors 1H-indole-3-acetamide compounds LILLY CO ELI (US) 1995-02-15 CN disclosed
EP-0620215-A1 1H-indole-3-acetamide derivatives as sPLA2 inhibitors ELI LILLY AND COMPANY (US) 1994-10-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162724-A1 Compounds exhibiting thrombopoietin-like activities MPL, THPO, TEK MAPT 4866/4885KDM4E 2972/4885ALDH1A1 2042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.